Skip to main content
Erschienen in: Heart Failure Reviews 6/2019

10.06.2019

Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review

verfasst von: Saeed Sheikh Gholami, Farbod Ebadi Fard Azar, Aziz Rezapour, Masih Tajdini

Erschienen in: Heart Failure Reviews | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Coronary artery disease (CAD) has significant social and economic implications. It is necessary to create tools to identify the most cost-effectiveness treatments, which can assist clinicians in their therapeutic decisions so that the maximum possible benefit is reached with the lowest possible cost. Effectiveness must be measured by final treatment goals in which the most effective interventions are those with the lowest costs. This study is aimed to systematically review and compare the studies conducted on the cost-effectiveness of the three coronary artery disease treatment strategies (medical treatment, percutaneous coronary intervention, and coronary artery bypass graft). In this systematic review, the databases NHS Economic Evaluation Database, Embase, MEDLINE, Science Direct, and Scopus were searched for studies on the cost-effectiveness of coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) compared to medical therapy (MT) in patients with coronary artery disease between 1 January 2004 to 30 September 2018. The quality appraisal of the included studies was examined using the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) statement. Out of 186 unique retrievals, 8 studies were included. The results showed that the all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, in most of the studies, quality-adjusted life years (QALY) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($212,800) for PCI v MT and the lowest ratio was observed in Brazil ($4403) for CABG v MT. Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the result of the present study, it seems that each three treatment strategies for CAD yielded improvements in QALY.
Literatur
1.
Zurück zum Zitat Allender S, Scarborough P, Peto V, Rayner M (2014).European cardiovascular disease statistics 2012 European heart network: Brussels. Allender S, Scarborough P, Peto V, Rayner M (2014).European cardiovascular disease statistics 2012 European heart network: Brussels.
2.
Zurück zum Zitat Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al (2013) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3):232 Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ et al (2013) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 129(3):232
3.
Zurück zum Zitat Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373(9670):1190–1197CrossRef Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kähler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ (2009) Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 373(9670):1190–1197CrossRef
4.
Zurück zum Zitat Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB (2007) A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9):1082–1089CrossRef Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB (2007) A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 115(9):1082–1089CrossRef
5.
Zurück zum Zitat Sculpher MJ, Buxton MJ, Seed P, Pocock SJ, Henderson RA, Parker J, Joy MD, Sowton E, Hampton JR, for RITA trial participants (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 344(8927):927–930CrossRef Sculpher MJ, Buxton MJ, Seed P, Pocock SJ, Henderson RA, Parker J, Joy MD, Sowton E, Hampton JR, for RITA trial participants (1994) Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet 344(8927):927–930CrossRef
6.
Zurück zum Zitat Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM, Buller N, Bonser R, van den Brand M, van Herwerden L, Morel MA, van Hout B, Arterial Revascularization Therapies Study Group (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344(15):1117–1124CrossRef Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJRM, Schönberger JPAM, Buller N, Bonser R, van den Brand M, van Herwerden L, Morel MA, van Hout B, Arterial Revascularization Therapies Study Group (2001) Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344(15):1117–1124CrossRef
7.
Zurück zum Zitat Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018) Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: a systematic review protocol. Medicine. 97(10):e9958CrossRef Rezapour A, Faradonbeh SB, Alipour V, Yusefvand M (2018) Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: a systematic review protocol. Medicine. 97(10):e9958CrossRef
8.
Zurück zum Zitat Chaitman BR, Ryan TJ, Kronmal RA, Foster ED, Frommer PL, Killip T (1990) Coronary artery surgery study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 16(5):1071–1078CrossRef Chaitman BR, Ryan TJ, Kronmal RA, Foster ED, Frommer PL, Killip T (1990) Coronary artery surgery study (CASS): comparability of 10 year survival in randomized and randomizable patients. J Am Coll Cardiol 16(5):1071–1078CrossRef
9.
Zurück zum Zitat Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King Iii SB (2000) Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty Versus Surgery Trial (EAST). Am J Cardiol 86(7):747–752CrossRef Weintraub WS, Becker ER, Mauldin PD, Culler S, Kosinski AS, King Iii SB (2000) Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty Versus Surgery Trial (EAST). Am J Cardiol 86(7):747–752CrossRef
10.
Zurück zum Zitat Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG, Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators (2008) Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients clinical perspective. Circulation: Cardiovascular Quality and Outcomes 1(1):12–20 Weintraub WS, Boden WE, Zhang Z, Kolm P, Zhang Z, Spertus JA, Hartigan P, Veledar E, Jurkovitz C, Bowen J, Maron DJ, O'Rourke R, Dada M, Teo KK, Goeree R, Barnett PG, Department of Veterans Affairs Cooperative Studies Program No. 424 (COURAGE Trial) Investigators and Study Coordinators (2008) Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients clinical perspective. Circulation: Cardiovascular Quality and Outcomes 1(1):12–20
11.
Zurück zum Zitat Vieira RDO, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL et al (2012) Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 126(11_suppl_1):S145–SS50CrossRef Vieira RDO, Hueb W, Hlatky M, Favarato D, Rezende PC, Garzillo CL et al (2012) Cost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of medicine, angioplasty, or surgery study (MASS) II trial. Circulation 126(11_suppl_1):S145–SS50CrossRef
12.
Zurück zum Zitat Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4ed. Oxford University Press: Oxford. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. 4ed. Oxford University Press: Oxford.
13.
Zurück zum Zitat Almasiankia A, Kavosi Z, Keshtkaran A, Jafari A, Goodarzi S (2015) Equity in health care financing among Iranian households. Shiraz: SEMJ. 16(11–12):6 Almasiankia A, Kavosi Z, Keshtkaran A, Jafari A, Goodarzi S (2015) Equity in health care financing among Iranian households. Shiraz: SEMJ. 16(11–12):6
14.
Zurück zum Zitat Ravangard R, Hatam N, Teimourizad A, Jafari A (2014) Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10). Int J Health Policy Manag 3(2):63–69CrossRef Ravangard R, Hatam N, Teimourizad A, Jafari A (2014) Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10). Int J Health Policy Manag 3(2):63–69CrossRef
15.
Zurück zum Zitat Jafari A, Rezapour A, Hajahmadi M (2018) Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev 23(5):1–8CrossRef Jafari A, Rezapour A, Hajahmadi M (2018) Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev 23(5):1–8CrossRef
16.
Zurück zum Zitat Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, on behalf of the CHEERS Task Force (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation 11(1):6CrossRef Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, on behalf of the CHEERS Task Force (2013) Consolidated health economic evaluation reporting standards (CHEERS) statement. Cost Effectiveness and Resource Allocation 11(1):6CrossRef
17.
Zurück zum Zitat Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (2009) Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120(25):2550–2558CrossRef Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (2009) Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120(25):2550–2558CrossRef
18.
Zurück zum Zitat Griffin S, Barber J, Manca A, Sculpher M, Thompson S, Buxton M et al (2007) Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 334(7594):624CrossRef Griffin S, Barber J, Manca A, Sculpher M, Thompson S, Buxton M et al (2007) Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 334(7594):624CrossRef
19.
Zurück zum Zitat Fidan D, Unal B, Critchley J, Capewell S (2007) Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010. J Assoc Physicians 100(5):277–289 Fidan D, Unal B, Critchley J, Capewell S (2007) Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010. J Assoc Physicians 100(5):277–289
20.
Zurück zum Zitat Brandão SMG, Rezende PC, Brunner-La Rocca H-P, Ju YT, de Lima ACP, Takiuti ME et al (2018) Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. CERA 16(1):55PubMed Brandão SMG, Rezende PC, Brunner-La Rocca H-P, Ju YT, de Lima ACP, Takiuti ME et al (2018) Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trial. CERA 16(1):55PubMed
21.
Zurück zum Zitat Caruba T, Katsahian S, Schramm C, Nelson AC, Durieux P, Bégué D et al (2014) Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One 9(6):e98371CrossRef Caruba T, Katsahian S, Schramm C, Nelson AC, Durieux P, Bégué D et al (2014) Treatment for stable coronary artery disease: a network meta-analysis of cost-effectiveness studies. PLoS One 9(6):e98371CrossRef
22.
Zurück zum Zitat Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martií SG (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacol Econ 27(11):919–929CrossRef Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martií SG (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacol Econ 27(11):919–929CrossRef
23.
Zurück zum Zitat Baltussen RMPM, Hutubessy RCW, Evans DB, Murray CJM (2002) Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Healthc 18(1):112–119 Baltussen RMPM, Hutubessy RCW, Evans DB, Murray CJM (2002) Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Healthc 18(1):112–119
24.
Zurück zum Zitat Ghabri S, Hamers FF, Josselin J-M, Harousseau J-L (2014) Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers’ submissions to the French National Authority for Health (HAS). Value Health 17(7):A441–A4A2CrossRef Ghabri S, Hamers FF, Josselin J-M, Harousseau J-L (2014) Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers’ submissions to the French National Authority for Health (HAS). Value Health 17(7):A441–A4A2CrossRef
25.
Zurück zum Zitat Limwattananon S (2014) Sensitivity analysis for handling uncertainty in an economic evaluation. J Med Assoc Thail 97:S59–S64 Limwattananon S (2014) Sensitivity analysis for handling uncertainty in an economic evaluation. J Med Assoc Thail 97:S59–S64
26.
Zurück zum Zitat Hatam N, Dehghani M, Habibian M, Jafari A (2015) Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractoryh Hodgkin and non-Hodgkin’s lymphoma in Iran. Iran J Cancer Prev 8(5):e4061CrossRef Hatam N, Dehghani M, Habibian M, Jafari A (2015) Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractoryh Hodgkin and non-Hodgkin’s lymphoma in Iran. Iran J Cancer Prev 8(5):e4061CrossRef
27.
Zurück zum Zitat Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P et al (2004) Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 25(24):2195–2203CrossRef Claude J, Schindler C, Kuster GM, Schwenkglenks M, Szucs T, Buser P et al (2004) Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 25(24):2195–2203CrossRef
28.
Zurück zum Zitat Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516CrossRef Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS, COURAGE Trial Research Group (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356(15):1503–1516CrossRef
29.
Zurück zum Zitat Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A (2010) Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 35(2):72–115CrossRef Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A (2010) Growing epidemic of coronary heart disease in low-and middle-income countries. Curr Probl Cardiol 35(2):72–115CrossRef
Metadaten
Titel
Cost-effectiveness of coronary artery bypass graft and percutaneous coronary intervention compared to medical therapy in patients with coronary artery disease: a systematic review
verfasst von
Saeed Sheikh Gholami
Farbod Ebadi Fard Azar
Aziz Rezapour
Masih Tajdini
Publikationsdatum
10.06.2019
Verlag
Springer US
Erschienen in
Heart Failure Reviews / Ausgabe 6/2019
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-019-09811-3

Weitere Artikel der Ausgabe 6/2019

Heart Failure Reviews 6/2019 Zur Ausgabe

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.